Integra LifeSciences Holdings Corporation

What they do

Integra manufactures and sells medical technologies across two reportable segments: Codman Specialty Surgical (CSS), about 70% of revenue, and Tissue Technologies (TT), about 30%. CSS covers neurosurgery, neurocritical care and ENT, and the company states it is the world leader in neurosurgery and one of the top three U.S. providers of precision, specialty and general surgical instruments. TT focuses on wound reconstruction and care plus private label products.

Revenue drivers

• Codman Specialty Surgical - Neuro — Part of the CSS segment, which is about 70% of total revenue; Q2 2026 neuro sales grew 1.9% organically led by Certas Plus, Bactiseal and CUSA.
• Codman Specialty Surgical - Instruments and ENT — Instruments grew 3.2% organically in Q2 2026; ENT declined 1.9% as MicroFrance ENT growth was offset by declines in other products.
• Tissue Technologies - wound reconstruction — Within the roughly 30%-of-revenue TT segment; Q2 2026 wound reconstruction declined mid-single digits, with DuraSorb growth and the PriMatrix relaunch offset by declines in MicroMatrix and Integra Skin.
• Tissue Technologies - private label — Also within TT; private label sales grew 4.7% in Q2 2026.

Recent performance

Q2 2026 revenue was $418.8 million, up 0.8% reported and 0.7% organic year over year. GAAP gross margin was 52.5% versus 50.4% a year earlier, and adjusted gross margin was 61.3%. GAAP net income was $4.5 million, or $0.06 per diluted share, versus a $(484.1) million net loss, or $(6.31) per share, in the prior-year quarter. Adjusted EBITDA was $78.4 million, 18.7% of revenue, and adjusted EPS was $0.56 versus $0.45. The company generated $22.8 million of operating cash flow in the quarter with net debt of $1.6 billion and a consolidated total leverage ratio of 4.1x.

Strategy

Management says it is improving supply reliability, advancing quality, and returning products to market with discipline. The company initiated production at its Braintree, Massachusetts facility and remains on track for a planned fourth-quarter relaunch of SurgiMend. It is implementing a Compliance Master Plan and pursuing restructuring and cost-saving initiatives. It also cites a more aligned commercial organization and continued reduction of balance sheet leverage.

Risks

• Regulatory compliance and quality remediation — The company continues to work through a Compliance Master Plan and has faced FDA observations and warning letters tied to quality systems and manufacture of certain products.
• EU MDR transition costs — EU MDR compliance spending was $41.9 million in 2025, and failure to obtain or maintain certifications within transitional periods could restrict sales in the EEA and other markets.
• Supply chain, tariffs and inflation — The company lists supply chain constraints, availability of critical raw materials and components, and cost inflation in materials, packaging and transportation among its risk factors.
• Leverage and liquidity — Net debt was $1.6 billion with a 4.1x consolidated total leverage ratio at June 30, 2026, against total liquidity of approximately $496 million.

Outlook

For Q3 2026, the company guides reported revenue of $410 million to $425 million, or 1.9% to 5.7% organic growth, and adjusted EPS of $0.53 to $0.61. Full-year reported revenue guidance was narrowed to $1.654 billion to $1.695 billion to reflect a stronger U.S. dollar, while full-year organic revenue growth guidance of 0.8% to 3.3% and adjusted EPS guidance of $2.40 to $2.50 were reaffirmed.